HARP - Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting | Benzinga
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.
Details of the IMS poster presentation are as follows:
Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Poster Number: P-292
Presenter: Sumit Madan, M.D., Banner MD Anderson Cancer Center
Session/Location: Poster Session 2, Trianti Hall Level II Foyer
Date: Thursday, September 28
Time: Viewing – 10:00 to 18:15 EEST / 3:00 a.m. to 1:15 p.m. ET, Presentation – 12:30 to 13:30 EEST / 5:30 a.m. to 6:30 a.m. ET
The poster ...